Cantor Fitzgerald Starts Salix Pharmaceuticals (SLXP) at Buy; Core Business Undervalued; Pipeline Risk Remains
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Price: $172.81 --0%
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald initiates coverage on Salix Pharmaceuticals (NASDAQ: SLXP) with a Buy. PT $56.00.
Cantor analyst says, "Salix offers strong revenue and earnings growth, good cash generation, long asset duration, and solid commercial execution. The company is also an attractive takeout target."
"Xifaxan: We view Xifaxan as a healthy asset with continued double-digit growth until 2020. Importantly, recent FDA guidance imposed a barrier to generic approval. Still, we believe that the risk around Xifaxan in diarrhea-predominant irritable bowel syndrome (IBS-D) has not diminished. Though the FDA advisory panel voted in favor of Salix’s proposed retreatment study design, we believe that the agency still has multiple concerns regarding approving Xifaxan for IBSD, and we still expect modifications to Salix’s proposed study design, which may set a higher hurdle for the company."
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $43.74 yesterday.
Cantor analyst says, "Salix offers strong revenue and earnings growth, good cash generation, long asset duration, and solid commercial execution. The company is also an attractive takeout target."
"Xifaxan: We view Xifaxan as a healthy asset with continued double-digit growth until 2020. Importantly, recent FDA guidance imposed a barrier to generic approval. Still, we believe that the risk around Xifaxan in diarrhea-predominant irritable bowel syndrome (IBS-D) has not diminished. Though the FDA advisory panel voted in favor of Salix’s proposed retreatment study design, we believe that the agency still has multiple concerns regarding approving Xifaxan for IBSD, and we still expect modifications to Salix’s proposed study design, which may set a higher hurdle for the company."
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $43.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Reading (RDI) Tops Q2 EPS by 4c
- Movano (MOVE) Misses Q2 EPS by 195c
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cantor Fitzgerald, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
